/ /

Michelle Dalton, ELS
Drug therapies improving refractive outcomes
Lines continue to blur as to what constitutes refractive surgery, and likely will continue to blur well into the future. Multiple compounds—phenylephrine and ketorolac 1%/0.3%, (Omidria, Omeros) and the “Dropless” line (Tri-Moxi/Tri-moxi-Vanc, Imprimis Pharmaceuticals)—are designed for use in cataract surgery, but their goal is to improve refractive outcomes. 2015 was the year they started to get some serious attention.
ROCK inhibitors show promise in glaucoma treatment
A novel class of drugs ‒ rho-kinase, or ROCK inhibitors ‒ appears to lower IOP by relaxing the trabecular meshwork.
ASCs are a winning proposition for cataract patients, surgeons
Working in an ambulatory surgery center can be a good choice for ophthalmologists, particularly cataract surgeons, because they let them use their time efficiently while delivering excellent care without the hassles of working in a larger hospital setting where ophthalmology may not be a priority.
Nitric oxide: A potential target for glaucoma treatment
Evidence suggests that nitric oxide can modify both mechanical and vascular events in primary open-angle glaucoma pathogenesis.
Ultra-widefield imaging: Coming into its own
Ultra-widefield (UWF) imaging provides clinicians a much broader view of the retinal periphery. The Optos California uses multiple UWF imaging modalities, including color, autofluorescence, fluorescein angiography (FA), and indocyanine green (ICG) angiography in a 200° picture.
Technologic advances integrate OCT into real-time surgeries
Researchers are conducting a prospective, multisurgeon, single-center study to evaluate multiple microscope integrated-prototypes with real-time surgeon feedback.

Poll

View Results